報價延遲最少15分鐘:2024/05/10 01:45 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.58 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-13.02/-0.19
|
|
企業價值
8.64M
|
| 資產負債 |
|
每股賬面淨值
0.94
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
34.07M
|
|
每股收益
5.71
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/10 01:45 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi. |